Home›Trial›NCT06523153
NCT06523153Phase 1ACTIVE NOT RECRUITING

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

Study Summary

A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants

Conditions
COVID-19
Interventions / Drugs
VYD2311Placebo
View on ClinicalTrials.gov ↗
Sponsor
IVVD
Invivyd Inc
Infectious Disease
D42/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorInvivyd, Inc.
Data Retrieved2026-04-11 04:18:15.922093+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 40 participants
Sponsor Catalyst Profile

Invivyd Inc (IVVD) is the sponsoring company for this trial. BiotechSign currently grades this company D (42/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

IVVD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.